Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HAMLET-BC

Financiado

Cerrado

Alpha1H A Unique Bladder Cancer Therapeutic Acting with Great Precision

Novel cancer treatments should ideally combine efficacy with selectivity. Tissue toxicity and side-effects are still the norm, however. Although new targeted therapies act with greater precision, the notion of tumour-specific cell... ver más

30/11/2022

HAMLET PHARMA AB

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

HAMLET PHARMA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

HAMLET PHARMA AB

2.20M€ | Lider

LIBERA EMPRESARIAL

195.97K€ | Participante

URBASER

352.63K€ | Participante

Proyectos interesantes

DESARROLLO DE PRIMER GENÉRICO PARA EL TRATAMI...

Medical Technol...

Pharmaceutical...

1M€ Cerrado

INNOBCT

Medical Technol...

Pharmaceuticals

71K€ Cerrado

PRE2018-085504

Medical Technol...

Cancer Research

93K€ Cerrado

DESARROLLO PRE CLÍNICO DE PÉPTIDOS INHIBIDORE...

Medical Technol...

Pharmaceutical...

357K€ Cerrado

EMBRACE

Medical Technol...

Cancer Research

178K€ Cerrado

INVESTIGACIÓN Y DESARROLLO DE UN FÁRMACO PARA...

Medical Technol...

Pharmaceutical...

629K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2020-06-11
Fecha Fin: 2022-11-30

Líder del proyecto

HAMLET PHARMA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Novel cancer treatments should ideally combine efficacy with selectivity. Tissue toxicity and side-effects are still the norm, however. Although new targeted therapies act with greater precision, the notion of tumour-specific cell death is justly regarded with scepticism. The Swedish company Hamlet Pharma provides new cancer treatments based on a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its proprietary drug complex, HAMLET (‘Human Alpha-lactalbumin Made LEthal to Tumour cells’) is derived from the human breast milk protein, alpha-lactalbumin, and represents a ground-breaking therapeutic solution with high tumour-killing capacity, high target specificity, killing >40 different types of tumour cells and no demonstrated toxicity. As such, it has the potential to revolutionize cancer treatment. Hamlet Pharma is now advancing HAMLET and the synthetic drug candidate Alpha1H along the clinical development pipeline as anti-cancer therapeutic for early stage bladder cancer. The company is focusing on bladder cancer given the high clinical need for more effective and safe treatment options. Bladder cancer has the highest recurrence rates (70%) and treatment costs per patient among all cancer types (total costs in Europe: >€4.9 billion). Recent successful outcomes include initial Phase I/II clinical trial data, proving that Alpha1H acts with high efficacy without any detectable toxicity. With the EIC Accelerator funding, Hamlet Pharma will finalise Phase I/II clinical safety and efficacy studies and advance development of Alpha1H towards a Phase III trial (i.e. ready for licensing deal or IPO). Conversations with potential licensing partners and investors are ongoing. Alpha1H will be an important showcase of the impact HAMLET will have on cancer treatment (expected cumulative revenues: €350M five years after market approval). Generated revenues will be reinvested into development of HAMLET for other cancer indications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores